...
首页> 外文期刊>Drugs of today: Medicamentos de actualidad >A report from the 2011 Alzheimer's Association International Conference (July 16-21 - Paris, France).
【24h】

A report from the 2011 Alzheimer's Association International Conference (July 16-21 - Paris, France).

机译:2011年阿尔茨海默氏症协会国际会议(7月16日至21日,法国巴黎)的报告。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Alzheimer's disease (AD) is indeed a source of sadness weighing on all those who after sharing a full life now depend on each other for the most basic functions. Nevertheless, besides the dramatic impact it imposes on the life of sufferers and their caregivers, AD, as well as other forms of dementia that affect the elderly, but also younger patients, also incurs in substantial healthcare costs for patients, their families and others, including society at large. The progressive aging of the population largely depending on improved preventive and curative healthcare is progressively worsening the situation because of the increasing number of elderly people and the consequent increase in dementia sufferers. Effective and cost-effective treatments are thus required for reversing, improving or preventing these cognitive impairments. Fortunately, research has resulted in therapeutic opportunities that were reviewed during the 2011 Alzheimer's Association International Conference (AAIC) in Paris, and will be briefly reviewed in the following report.
机译:阿尔茨海默氏病(AD)的确是使所有人感到悲伤的根源,这些人一生都过着完整的生活,而现在他们在最基本的功能上相互依赖。然而,除了会给患者及其护理人员的生活带来巨大影响之外,AD以及影响老年人(包括年轻患者)的其他形式的痴呆症,也会给患者,其家人和其他人带来可观的医疗费用,包括整个社会。人口的逐步老龄化在很大程度上取决于改善的预防性和治疗性医疗保健,这使情况逐渐恶化,原因是老年人数量增加,因此痴呆症患者也随之增加。因此,需要有效且划算的治疗方法来逆转,改善或预防这些认知障碍。幸运的是,研究产生了治疗上的机会,该机会在2011年巴黎阿尔茨海默氏症协会国际会议(AAIC)上进行了回顾,并将在以下报告中进行简要回顾。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号